Regulatory T Cells, IL10 and IL6 in HCV Related Hepatocellular Carcinoma after Transarterial Chemoembolization (TACE).
Regulatory T Cells, IL10 and IL6 in HCV Related Hepatocellular Carcinoma after Transarterial Chemoembolization (TACE).
复制标题
DOI：
--
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Ehsan A. Hassan;Entsar H Ahmed;A. Nafee;Nourhan El-Gafary;H. Hetta;M. El-Mokhtar
中科院分区：
文献类型：
--
作者：
Ehsan A. Hassan;Entsar H Ahmed;A. Nafee;Nourhan El-Gafary;H. Hetta;M. El-Mokhtar
肝细胞癌是肝脏的主要恶性肿瘤。肿瘤可以招募和促进调节性T细胞(Tregs)的扩张，从而抑制抗肿瘤免疫反应，从而维持生存和发展。此外，有强有力的证据表明，细胞因子在促进肝癌的发生和发展中具有潜在的作用。我们的目的是评估经动脉化疗栓塞术(TACE)前后Treg细胞频率和血清IL-6、IL-10水平。我们在Assiut大学医院进行了一项横断面研究，其中包括34名肝细胞癌患者和10名匹配的明显健康的对照组。用流式细胞仪检测外周血Treg频率。采用双抗体夹心ELISA法检测患者TACE前后血清IL-6、IL-10水平。肝癌患者血清IL-6和IL-10水平显著高于对照组(P=0.0002，P<；0.0001)。然而，在治疗后，IL6和IL10水平升高，然后下降到基线水平。肿瘤体积较大(≥5 cm)的患者IL 6和IL 10水平均高于肿瘤较小的患者。此外，与对照组相比，肝癌患者的Treg细胞频率更高(P=0.002)。治疗前后Treg细胞频率与IL10无明显相关性(r=0.38，P=0.30)。结论：肝细胞癌患者IL-6、IL-10水平及Tregs百分率均显著高于正常对照组。化疗栓塞术后Treg水平会发生改变。IL-6有可能反映患者治疗后的病情，有助于监测治疗情况。
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver. Tumors can recruit and promote the expansion of regulatory T cells (Tregs) to suppress antitumor immune responses for survival and progression. Furthermore, there is a strong evidence for the potential roles of cytokines in promoting HCC carcinogenesis and progression. We aimed to evaluate the frequency of Treg cells and serum levels of IL6 and IL10 before and after transarterial chemoembolization (TACE). We carried out a cross-sectional study at Assiut University hospitals that included 34 HCC patients and 10 matched apparently healthy controls. Peripheral Treg frequency was evaluated by Flow cytometry. IL6 and IL10 serum levels were evaluated by ELISA before and after TACE. HCC patients had a significantly higher level of IL6 and IL10 when compared to the control group (P=0.0002, P < 0.0001), respectively. However, after treatment, there was an elevation in the levels of IL6 and IL10 followed by a decrease to the baseline levels. Patients with large tumors (≥5 cm) showed higher levels of both IL 6 and IL 10 than those with smaller tumors. Moreover, HCC patients showed a higher frequency of Treg cells in comparison to the controls (P=0.002). No significant correlation was observed between the frequency of Treg cells and IL10 before and after treatment (r=0.38, P=0.30). In conclusion, HCC patients have significantly higher levels of IL 6, IL 10 and a higher percentage of Tregs than control individuals. Treg levels are altered after chemoembolization. IL 6 have a potential in reflecting the patient's condition after treatment, thus, can help in monitoring therapy.